PortfoliosLab logoPortfoliosLab logo
BNGO vs. PFE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BNGO vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bionano Genomics, Inc. (BNGO) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BNGO achieves a -15.03% return, which is significantly lower than PFE's 5.18% return.


BNGO

1D
3.17%
1M
4.84%
YTD
-15.03%
6M
-24.86%
1Y
-64.77%
3Y*
-86.03%
5Y*
-80.06%
10Y*

PFE

1D
-0.82%
1M
-2.06%
YTD
5.18%
6M
2.42%
1Y
16.11%
3Y*
-7.32%
5Y*
-3.51%
10Y*
1.85%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BNGO vs. PFE - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BNGO
Bionano Genomics, Inc.
-15.03%-91.16%-84.74%-87.05%-51.17%-2.92%148.39%-76.34%-25.04%
PFE
Pfizer Inc.
5.18%0.65%-2.22%-41.26%-10.41%66.70%3.07%-6.91%-0.17%

Correlation

The correlation between BNGO and PFE is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (All Time)
Calculated using the full available price history since Sep 24, 2018

0.13

The correlation between BNGO and PFE shifts across timeframes, from 0.13 (all time) to 0.24 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

EPS

BNGO:

-$6.55

PFE:

$1.31

PS Ratio

BNGO:

0.21

PFE:

2.28

Total Revenue (TTM)

BNGO:

$22.06M

PFE:

$63.32B

Gross Profit (TTM)

BNGO:

$3.32M

PFE:

$43.91B

EBITDA (TTM)

BNGO:

-$23.09M

PFE:

$16.94B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BNGO vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNGO
BNGO Risk / Return Rank: 1111
Overall Rank
BNGO Sharpe Ratio Rank: 99
Sharpe Ratio Rank
BNGO Sortino Ratio Rank: 1010
Sortino Ratio Rank
BNGO Omega Ratio Rank: 88
Omega Ratio Rank
BNGO Calmar Ratio Rank: 99
Calmar Ratio Rank
BNGO Martin Ratio Rank: 1818
Martin Ratio Rank

PFE
PFE Risk / Return Rank: 6161
Overall Rank
PFE Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
PFE Sortino Ratio Rank: 5757
Sortino Ratio Rank
PFE Omega Ratio Rank: 5555
Omega Ratio Rank
PFE Calmar Ratio Rank: 6767
Calmar Ratio Rank
PFE Martin Ratio Rank: 6565
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNGO vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bionano Genomics, Inc. (BNGO) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BNGOPFEDifference
Sharpe ratioReturn per unit of total volatility

-1.48

Sortino ratioReturn per unit of downside risk

-2.27

Omega ratioGain probability vs. loss probability

0.83

1.14

-0.31

Calmar ratioReturn relative to maximum drawdown

-0.83

1.41

-2.24

Martin ratioReturn relative to average drawdown

-1.08

2.91

-3.99

BNGO vs. PFE - Sharpe Ratio Comparison

The current BNGO Sharpe Ratio is -0.80, which is lower than the PFE Sharpe Ratio of 0.68. The chart below compares the historical Sharpe Ratios of BNGO and PFE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BNGOPFEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.80

0.68

-1.48

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.89

-0.14

-0.75

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.08

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.34

0.23

-0.57

Drawdowns

BNGO vs. PFE - Drawdown Comparison

The maximum BNGO drawdown since its inception was -99.99%, which is greater than PFE's maximum drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for BNGO and PFE.


Loading charts...

Drawdown Indicators


BNGOPFEDifference

Max Drawdown

Largest peak-to-trough decline

-99.99%

-58.96%

-41.03%

Max Drawdown (1Y)

Largest decline over 1 year

-77.85%

-11.47%

-66.38%

Max Drawdown (3Y)

Largest decline over 3 years

-99.76%

-40.75%

-59.01%

Max Drawdown (5Y)

Largest decline over 5 years

-99.98%

-58.96%

-41.02%

Max Drawdown (10Y)

Largest decline over 10 years

-58.96%

Current Drawdown

Current decline from peak

-99.99%

-47.49%

-52.50%

Average Drawdown

Average peak-to-trough decline

-83.70%

-17.68%

-66.02%

Ulcer Index

Depth and duration of drawdowns from previous peaks

60.12%

5.54%

+54.58%

Volatility

BNGO vs. PFE - Volatility Comparison

Bionano Genomics, Inc. (BNGO) has a higher volatility of 11.64% compared to Pfizer Inc. (PFE) at 4.07%. This indicates that BNGO's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BNGOPFEDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.64%

4.07%

+7.57%

Volatility (6M)

Calculated over the trailing 6-month period

45.02%

14.64%

+30.38%

Volatility (1Y)

Calculated over the trailing 1-year period

81.10%

23.85%

+57.25%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

90.54%

25.49%

+65.05%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

191.66%

23.88%

+167.78%

Dividends

BNGO vs. PFE - Dividend Comparison

BNGO has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.79%.


PositionTTM20252024202320222021202020192018201720162015
BNGO
Bionano Genomics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PFE
Pfizer Inc.
6.79%6.91%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.53%3.69%3.47%

Financials

BNGO vs. PFE - Financials Comparison

This section allows you to compare key financial metrics between Bionano Genomics, Inc. and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B25.00B20222023202420252026
6.69K
14.45B
(BNGO) Total Revenue
(PFE) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BNGO and PFE have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BNGO has higher volatility (11.64%) compared to PFE (4.07%). In terms of maximum drawdown, BNGO dropped -99.99% vs PFE's -58.96%.

PFE currently has the higher Sharpe Ratio (0.68 vs -0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BNGO and PFE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer